Filing Flows

Filing Flows › Companies › Celldex Therapeutics › Cash flow

Celldex Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$66.7M in Q3 2026 · −$260M over twelve months

Operating cash flow−$65.0M
Capital spending−$1.7M
Free cash flow−$66.7M

Analysis

In Q3 2026, Celldex Therapeutics generated −$65.0M of operating cash flow and spent $1.7M on capital projects, leaving free cash flow of −$66.7M. That is $17.6M less than in Q3 2025 (−$49.1M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$252M; the largest uses were operating cash flow ($252M), other investing ($76.8M), capital spending ($7.8M); besides operations, cash came from other financing ($324M), shares issued ($3.6M); the cash balance fell by $9.1M.

Operating cash flow was −$65.0M against net income of −$75.6M. The largest differences: stock-based pay +$11.0M, prepaid and other assets −$5.1M, depreciation & amortization +$1.2M.

Free cash flow

Celldex Therapeutics: free cash flow by quarterCelldex Therapeutics: free cash flow by quarter−$33.2MQ4 2024−$54.6MQ1 2025−$44.7MQ2 2025−$49.1MQ3 2025−$65.2MQ4 2025−$67.2MQ1 2026−$60.6MQ2 2026−$66.7MQ3 2026
Operating cash flow less capital spending.
Celldex Therapeutics: operating cash flow against capital spendingCelldex Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$32.5M$756KQ4 2024−$54.4M$265KQ1 2025−$44.0M$728KQ2 2025−$48.6M$440KQ3 2025−$63.9M$1.3MQ4 2025−$65.6M$1.6MQ1 2026−$57.4M$3.2MQ2 2026−$65.0M$1.7MQ3 2026
Latest (Q3 2026): Operating cash flow −$65.0M, Capital spending $1.7M.

Capital allocation, year by year

Celldex Therapeutics: where the cash came from (up) and went (down), by fiscal yearCelldex Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$60.9MFY2021: Shares issued $272MFY2021: Asset sales $27KFY2021: Capital spending −$1.2M$272MFY2021FY2022: Operating cash flow −$104MFY2022: Shares issued $4.1MFY2022: Asset sales $69KFY2022: Capital spending −$1.8M$4.1MFY2022FY2023: Operating cash flow −$107MFY2023: Shares issued $218MFY2023: Capital spending −$1.8M$218MFY2023FY2024: Operating cash flow −$158MFY2024: Shares issued $441MFY2024: Capital spending −$1.9M$441MFY2024FY2025: Operating cash flow −$211MFY2025: Shares issued $2.4MFY2025: Capital spending −$2.7M$2.4MFY2025
Over these 5 years operating cash flow totalled −$641M; the largest uses were operating cash flow ($641M) and capital spending ($9.5M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$650M
Debtnone
Net cash$650M
Cash runway2.5 years

Celldex Therapeutics is burning cash: its operations consume cash, a free cash flow of −$260M a year at the current rate against $650M of cash and investments: a runway of about 2.5 years before any new financing.

Where the cash came from and went

Celldex Therapeutics: sources (+) and uses (−) of cash, Q3 2026Celldex Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$65.0MOther investing$45.1MCash drawn (+) / kept (−)$20.5MCapital spending−$1.7MShares issued$1.1M
Celldex Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Celldex Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$324MOperating cash flow−$252MOther investing−$76.8MCash drawn (+) / kept (−)$9.1MCapital spending−$7.8MShares issued$3.6M

From profit to cash

Celldex Therapeutics: net income to operating cash flow, Q3 2026Celldex Therapeutics: net income to operating cash flow, Q3 2026Net income−$75.6MDepreciation & amortization$1.2MStock-based pay$11.0MGains on disposals$47KReceivables−$125KPayables−$823KPrepaid and other assets−$5.1MOther liabilities−$567KOperating cash flow−$65.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$65.0M−$1.7M$1.1M$20.5M−$66.7M
Q2 2026−$57.4M−$3.2M$825K−$11.7M−$60.6M
Q1 2026−$65.6M−$1.6M$327K−$6.9M−$67.2M
Q4 2025−$63.9M−$1.3M$1.3M$7.2M−$65.2M
Q3 2025−$48.6M−$440K$774K−$13.0M−$49.1M
Q2 2025−$44.0M−$728K$63K−$5.9M−$44.7M
Q1 2025−$54.4M−$265K$202K$11.2M−$54.6M
Q4 2024−$32.5M−$756K$386K$8.0M−$33.2M

Celldex Therapeutics: income statement and cash flow

Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year). The chart follows the revenue to costs, profit and cash.

Celldex Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.